Jessica A Pollard1, Michael Loken2, Robert B Gerbing2, Susana C Raimondi2, Betsy A Hirsch2, Richard Aplenc2, Irwin D Bernstein2, Alan S Gamis2, Todd A Alonzo2, Soheil Meshinchi2. 1. Jessica A. Pollard, Maine Medical Center, Portland, ME; and Tufts University, Boston, MA; Michael Loken, Hematologics; Irwin D. Bernstein and Soheil Meshinchi, Fred Hutchinson Cancer Research Center; Irwin D. Bernstein and Soheil Meshinchi, University of Washington, Seattle, WA; Robert B. Gerbing and Todd A. Alonzo, Children's Oncology Group, Arcadia; Todd A. Alonzo, Keck School of Medicine of University of Southern California, Los Angeles, CA; Susana C. Raimondi, St Jude Children's Research Hospital, Memphis, TN; Betsy Hirsch, University of Minnesota Cancer Center, Minneapolis, MN; Richard Aplenc, Children's Hospital of Philadelphia, Philadelphia, PA; and Alan S. Gamis, Children's Mercy Hospitals and Clinics, Kansas City, MO. jpollard@mmc.org. 2. Jessica A. Pollard, Maine Medical Center, Portland, ME; and Tufts University, Boston, MA; Michael Loken, Hematologics; Irwin D. Bernstein and Soheil Meshinchi, Fred Hutchinson Cancer Research Center; Irwin D. Bernstein and Soheil Meshinchi, University of Washington, Seattle, WA; Robert B. Gerbing and Todd A. Alonzo, Children's Oncology Group, Arcadia; Todd A. Alonzo, Keck School of Medicine of University of Southern California, Los Angeles, CA; Susana C. Raimondi, St Jude Children's Research Hospital, Memphis, TN; Betsy Hirsch, University of Minnesota Cancer Center, Minneapolis, MN; Richard Aplenc, Children's Hospital of Philadelphia, Philadelphia, PA; and Alan S. Gamis, Children's Mercy Hospitals and Clinics, Kansas City, MO.
Abstract
PURPOSE: CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. PATIENTS AND METHODS: CD33 expression levels were prospectively quantified by multidimensional flow cytometry in 825 patients enrolled in Children's Oncology Group AAML0531 and correlated with response to GO. RESULTS: Patients with low CD33 expression (lowest quartile of expression [Q1]) had no benefit with the addition of GO to conventional chemotherapy (relapse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456). However, patients with higher CD33 expression (Q2 to Q4) had significantly reduced RR (GO 32% v No-GO 49%, P < .001) and improved EFS (GO 53% v No-GO 41%, P = .005). This differential effect was observed in all risk groups. Specifically, low-risk (LR), intermediate-risk (IR), and high-risk (HR) patients with low CD33 expression had similar outcomes regardless of GO exposure, whereas the addition of GO to conventional chemotherapy resulted in a significant decrease in RR and disease-free survival (DFS) for patients with higher CD33 expression (LR RR, GO 13% v No-GO 35%, P = .001; LR DFS, GO 79% v No-GO 59%, P = .007; IR RR, GO 44% v No-GO 57%, P = .044; IR DFS, GO 51% v No-GO 40%, P = .078; HR RR, GO 40% v No-GO 73%, P = .016; HR DFS, GO 47% v No-GO 28%, P = .135). CONCLUSION: We demonstrate that GO lacks clinical benefit in patients with low CD33 expression but significantly reduces RR and improves EFS in patients with high CD33 expression, which suggests a role for CD33-targeted therapeutics in subsets of pediatric AML.
RCT Entities:
PURPOSE:CD33 is variably expressed on acute myeloid leukemia (AML) blasts and is targeted by gemtuzumab ozogamicin (GO). GO has shown benefit in both adult and pediatric AML trials, yet limited data exist about whether GO response correlates with CD33 expression level. PATIENTS AND METHODS: CD33 expression levels were prospectively quantified by multidimensional flow cytometry in 825 patients enrolled in Children's Oncology Group AAML0531 and correlated with response to GO. RESULTS:Patients with low CD33 expression (lowest quartile of expression [Q1]) had no benefit with the addition of GO to conventional chemotherapy (relapse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456). However, patients with higher CD33 expression (Q2 to Q4) had significantly reduced RR (GO 32% v No-GO 49%, P < .001) and improved EFS (GO 53% v No-GO 41%, P = .005). This differential effect was observed in all risk groups. Specifically, low-risk (LR), intermediate-risk (IR), and high-risk (HR) patients with low CD33 expression had similar outcomes regardless of GO exposure, whereas the addition of GO to conventional chemotherapy resulted in a significant decrease in RR and disease-free survival (DFS) for patients with higher CD33 expression (LR RR, GO 13% v No-GO 35%, P = .001; LR DFS, GO 79% v No-GO 59%, P = .007; IR RR, GO 44% v No-GO 57%, P = .044; IR DFS, GO 51% v No-GO 40%, P = .078; HR RR, GO 40% v No-GO 73%, P = .016; HR DFS, GO 47% v No-GO 28%, P = .135). CONCLUSION: We demonstrate that GO lacks clinical benefit in patients with low CD33 expression but significantly reduces RR and improves EFS in patients with high CD33 expression, which suggests a role for CD33-targeted therapeutics in subsets of pediatric AML.
Authors: Jeffrey E Rubnitz; Hiroto Inaba; Gary Dahl; Raul C Ribeiro; W Paul Bowman; Jeffrey Taub; Stanley Pounds; Bassem I Razzouk; Norman J Lacayo; Xueyuan Cao; Soheil Meshinchi; Barbara Degar; Gladstone Airewele; Susana C Raimondi; Mihaela Onciu; Elaine Coustan-Smith; James R Downing; Wing Leung; Ching-Hon Pui; Dario Campana Journal: Lancet Oncol Date: 2010-05-05 Impact factor: 41.316
Authors: Michael R Loken; Todd A Alonzo; Laura Pardo; Robert B Gerbing; Susana C Raimondi; Betsy A Hirsch; Phoenix A Ho; Janet Franklin; Todd M Cooper; Alan S Gamis; Soheil Meshinchi Journal: Blood Date: 2012-05-30 Impact factor: 22.113
Authors: Jessica A Pollard; Todd A Alonzo; Michael Loken; Robert B Gerbing; Phoenix A Ho; Irwin D Bernstein; Susana C Raimondi; Betsy Hirsch; Janet Franklin; Roland B Walter; Alan Gamis; Soheil Meshinchi Journal: Blood Date: 2012-02-29 Impact factor: 22.113
Authors: Todd M Cooper; Janet Franklin; Robert B Gerbing; Todd A Alonzo; Craig Hurwitz; Susana C Raimondi; Betsy Hirsch; Franklin O Smith; Prasad Mathew; Robert J Arceci; James Feusner; Robert Iannone; Robert S Lavey; Soheil Meshinchi; Alan Gamis Journal: Cancer Date: 2011-07-15 Impact factor: 6.860
Authors: Roland B Walter; Todd A Alonzo; Robert B Gerbing; Phoenix A Ho; Franklin O Smith; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Janet L Franklin; Craig A Hurwitz; Michael R Loken; Soheil Meshinchi Journal: J Clin Oncol Date: 2010-04-26 Impact factor: 44.544
Authors: Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley Journal: J Clin Oncol Date: 2010-12-20 Impact factor: 44.544
Authors: Stephen H Petersdorf; Kenneth J Kopecky; Marilyn Slovak; Cheryl Willman; Thomas Nevill; Joseph Brandwein; Richard A Larson; Harry P Erba; Patrick J Stiff; Robert K Stuart; Roland B Walter; Martin S Tallman; Leif Stenke; Frederick R Appelbaum Journal: Blood Date: 2013-04-16 Impact factor: 22.113
Authors: Eva Jager; Vincent H J van der Velden; Jeroen G te Marvelde; Roland B Walter; Zvia Agur; Vladimir Vainstein Journal: PLoS One Date: 2011-09-07 Impact factor: 3.240
Authors: Kelly J Norsworthy; Chia-Wen Ko; Jee Eun Lee; Jiang Liu; Christy S John; Donna Przepiorka; Ann T Farrell; Richard Pazdur Journal: Oncologist Date: 2018-04-12
Authors: George S Laszlo; Mary E Beddoe; Colin D Godwin; Olivia M Bates; Chelsea J Gudgeon; Kimberly H Harrington; Roland B Walter Journal: Haematologica Date: 2018-08-16 Impact factor: 9.941
Authors: Soheil Meshinchi; Jessica A Pollard; Katherine Tarlock; Todd A Alonzo; Yi-Cheng Wang; Robert B Gerbing; Rhonda Ries; Michael R Loken; Laura Pardo; Tiffany Hylkema; Jason Joaquin; Leela Sarukkai; Susana C Raimondi; Betsy Hirsch; Lillian Sung; Richard Aplenc; Irwin Bernstein; Alan S Gamis Journal: Clin Cancer Res Date: 2019-06-10 Impact factor: 12.531
Authors: Jatinder K Lamba; Andrew P Voigt; Lata Chauhan; Miyoung Shin; Richard Aplenc; Lisa Eidenschink Brodersen; Alan S Gamis; Soheil Meshinchi; Michael R Loken Journal: Leuk Lymphoma Date: 2018-01-10